Pds biotech to present updated versatile-002 data at esmo congress 2024

Princeton, n.j., sept. 09, 2024 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the versatile-002 trial evaluating first-line treatment with versamune® hpv (formerly pds0101) in combination with keytruda® (pembrolizumab) in patients with hpv16-positive recurrent/metastatic head and neck squamous cell carcinoma (hnscc) during a poster presentation at the upcoming european society for medical oncology (esmo) congress 2024 on september 14, 2024, in barcelona, spain.
PDSB Ratings Summary
PDSB Quant Ranking